Stopangin-teva 0.2% 30ml spray for topical use

Stopangin-teva 0.2% 30ml spray for topical use

pharmachologic effect

Stopangin is an antiseptic for topical use. It also has antifungal activity and analgesic properties when applied to the mucous membrane. Stopangin has an enveloping effect. The effect lasts 10 - 12 hours.

Composition and release form Stopangin-teva 0.2% 30ml spray for topical use

1 bottle contains:

• Active substance: hexethidine - 0.0577 g;
• Excipients: methyl salicylate; anise essential oil; eucalyptus essential oil; orange flower essential oil; sassafras essential oil; peppermint essential oil; levomenthol; sodium saccharinate monohydrate; glycerol 85%; ethanol 96%.

Directions for use and doses

Locally. The drug should be used after meals or between meals for 5–7 days. Remove the protective cap and attach the applicator. Press 2-3 times so that the solution enters the sprayer. Then hold your breath and spray on the affected area. The procedure should be carried out 2 times a day, unless the doctor prescribes otherwise. After use, the applicator should be rinsed with warm water.

Indications for use Stopangin-teva 0.2% 30ml spray for topical use

• inflammatory diseases of the oral cavity and larynx (tonsillitis, tonsillitis, pharyngitis, stomatitis, aphthae, glossitis, periodontal disease and periodontopathies, infection of the alveoli);
• fungal diseases of the oral cavity and larynx (thrush);
• before and after surgical interventions, as well as injuries to the oral cavity and larynx;
• as an adjuvant in the complex treatment of sore throats.

Contraindications

For dry atrophic pharyngitis, children under 8 years of age, as well as during pregnancy (1st trimester).

Application of Stopangin-teva 0.2% 30ml spray for topical use during pregnancy and breastfeeding

Stopangin is contraindicated during pregnancy, lactation and children under 8 years of age.

Side effects of Stopangin-teva 0.2% 30ml spray for topical use

Local reactions: possible burning sensation of the oral mucosa (quickly passes spontaneously).

Other: in exceptional cases, allergic reactions are possible in patients with hypersensitivity; If the drug is accidentally swallowed while rinsing, nausea may occur (it goes away spontaneously).

If unusual reactions occur, the patient should consult a doctor about the advisability of further use of the drug.

Stopangin

Stopangin (hexeditin + methyl salicylate + essential oils) is an external antiseptic. It has antimycotic activity and analgesic properties. Endowed with enveloping properties (forms colloidal solutions with water and protects mucous membranes and skin from the irritating effects of physical and chemical factors). Used to treat acute inflammation of the components of the lymphatic pharyngeal ring, incl. palatine tonsils, inflammation of the mucous membrane of the pharynx, oral cavity, tongue, periodontal tissue, fungal infections of the oropharynx and larynx, before and after operations in the oral cavity. Inflammatory diseases of the oral cavity and pharynx are among the most common in the structure of the general morbidity of the human population. Most often, their culprits are bacteria, fungi and viruses. Today, the treatment of these diseases, in addition to pathogenetic therapy, involves the use of drugs for local action on the inflamed areas of the mucous membranes. One of these drugs is Stopangin. The effect of this combination drug is determined by its constituent components. Hexeditin is a disinfectant with antibacterial, antimycotic and antiviral effects. Effective against streptococci, staphylococci, pneumococci, corynebacteria, listeria, salmonella, candida. Essential oils in combination exhibit a disinfectant and anti-inflammatory effect.

Methyl salicylate is a local analgesic and anti-inflammatory agent. Stopangin is contraindicated in case of individual intolerance to the components, “dry” atrophic inflammation of the larynx, in the 1st trimester of pregnancy. In pediatric practice, the drug is used starting from the age of 8. Undesirable reactions may include a transient sensation of itching and burning of the oropharyngeal mucosa. In rare cases, allergic reactions are possible. Injections are made using a special applicator. Before use, you must press the bottle 2-3 times so that the sprayer is filled with solution. When injecting, you should hold your breath. The frequency of use of the drug is 2-3 times a day. The optimal time to take it is after or between meals. Stopangin should not be inhaled (which is why the drug is not recommended for children under 8 years of age). Care should be taken to avoid getting the drug in the eyes. The possibility or necessity of combining Stopangin with other drugs is assessed by the attending physician. If after three days of treatment there is no improvement in the clinical situation, you should seek medical advice. The maximum duration of use of Stopangin for self-medication is 5-7 days. The drug contains ethanol, which must be taken into account by motorists and persons working with potentially dangerous mechanisms.

Compound

Experience with the use of the drug stopangin in the treatment of inflammatory diseases of the pharynx in children

Chronic tonsillitis, which is a long-term inflammatory process in the palatine tonsils, is one of the most pressing problems in pediatric otorhinolaryngology. This is due to the extremely important role of the tonsils in the formation of mechanisms of specific and nonspecific defense of the child’s body during its growth. Chronic tonsillitis accounts for 4 to 9% of all diseases in children [1]. In the group of frequently ill children, chronic tonsillitis accounts for 43% [2]. The disease is manifested by frequent sore throats in combination with general toxic-allergic phenomena: periodic rise in temperature, tonsillogenic intoxication, accompanied by weakness, as well as periodic pain in the joints and heart. Among the complications of chronic tonsillitis, it is necessary to highlight lateral and retropharyngeal abscesses, as well as rheumatism, diseases of the urinary system, prostate gland, and meninges [3]. Thus, chronic tonsillitis must be considered as a focal infection, the elimination of which is an extremely important part of the task of maintaining the health of the child as a whole, as well as preventing diseases associated with chronic tonsillitis [4].

Due to the empirical nature of prescribing antibacterial therapy and the widespread prevalence of resistant strains of the main pathogens, recently increasing importance has been given to the inclusion of locally active drugs in the treatment regimen. One of the promising areas is the prescription of drugs that combine antiseptic, anti-inflammatory and analgesic effects. The Ivex drug Stopangin meets these requirements.

Stopangin is a combination drug that contains three main components: hexetidine, methyl salicylate and a complex of essential oils. The main active ingredient, hexetidine, has a wide range of pharmacological properties. Hexetidine has a bactericidal and bacteriostatic effect, and has an antifungal and antiviral effect. The drug is active against S. aureus, S.pyogenes, S.epidermidis, Clostridium perfringens, Mycobacterium tuberculosis, Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, Candida spp., Actinomyces spp., Trichophyton spp., Histoplasma capsulatum, etc. [5] . It is reported that strains with acquired resistance to antibiotics do not develop cross-resistance to hexetidine, even with prolonged treatment with this drug for 5 months. In addition to its antimicrobial properties, hexetidine has a hemostatic and analgesic effect, which justifies its use after tonsillectomy [5]. Unlike chlorhexidine, it is low-toxic and can therefore be prescribed to children. Methyl salicylate has analgesic and anti-inflammatory effects. Stopangin is available in the form of a spray and a solution for gargling. stopangin contains a complex of essential oils: anise, eucalyptus, sassafras, clove, peppermint oil. They have not only softening, but also antiseptic effects.

In the Department of Ear, Nose and Throat Diseases of the Federal State Institution MNIIPiDH Roszdrav, a study was conducted on the effectiveness of the drug stopangin in the treatment of chronic compensated tonsillitis (CCT) and chronic decompensated tonsillitis (CDT) in children in comparison with traditional therapy. During the study, the following tasks were solved: assessment of the anti-inflammatory and analgesic properties of the drug, both in the conservative treatment of chronic tonsillitis and after tonsillectomy, as well as the effect of stopangin on the pathogenic microflora of the pharynx before and after treatment.

The study involved 51 patients aged 5 to 17 years: 31 of them with CCT and 20 patients with CDT after tonsillectomy. All children underwent a course of antibacterial therapy before hospitalization, some twice. The patient examination plan included a daily examination with an assessment of the dynamics of the condition of the pharyngeal mucosa and taking into account the patient’s subjective assessment of the severity of the pain syndrome on a visual analogue scale. All patients had their pharyngeal microflora examined before and after treatment.

All patients were divided into two groups (Table). Patients of the main group received treatment with Stopangin: the lacunae of the tonsils were washed with a solution of the drug 2 times a day (in patients after tonsillectomy, the oropharynx was rinsed), as well as the pharynx was irrigated with Stopangin spray 3 times a day. Patients in the control group received traditional therapy: washing the lacunae of the tonsils, rinsing the oropharynx with a solution of furatsilin or saline with the addition of eucalyptus tincture (1:10) and lubricating the pharynx with Lugol's solution. Children with HDT after tonsillectomy additionally had their throats irrigated with Cameton aerosol 3 times a day. The course of treatment was 7–8 days.

All patients initially complained of sore and dry throat and pain when swallowing. 50% of children had symptoms of intoxication: weakness, fatigue, increased sweating, periodic rise in temperature to low-grade levels, “flying” pain in the joints. Pharyngoscopy revealed in most children severe hyperemia of the anterior palatine arches and hypertrophy of the tonsils from grades I to III, usually with purulent plugs in the lacunae. With pharyngitis, the clinical picture was complemented by thickening of the lateral ridges of the pharynx or the presence of lymphoid granules on the posterior wall of the pharynx. With tonsillomycosis, there was a characteristic white coating on the surface of the tonsils.

All patients underwent a study of the pharyngeal microflora before starting treatment. In the first group, monoflora was sown in 4 patients; in the remaining 17, microorganisms were sown in association. In the second group, a monoculture was sown in 1 patient and an association of microorganisms was sown in 10 patients.

The study demonstrated a higher therapeutic effectiveness of the drug Stopangin compared to traditional therapy. In patients with CCT who received stopangin, by the 2–3rd day of treatment, the disappearance of pain and discomfort in the throat was noted; on the 3–4th day, hyperemia of the pharynx mucosa disappeared and the lymphoid tissue of the tonsils was significantly reduced. A decrease or disappearance of plaque on the tonsils with tonsillomycosis was observed on days 5–6. In the control group of children with CCT, the above symptoms resolved 2–3 days later.

In children with HDT (after tonsillectomy) with the use of stopangin, the pain syndrome resolved on the 3rd–4th day, by which time the hyperemia of the mucous membrane and swelling of the arches and uvula of the soft palate also disappeared. On the 4th–5th day, the almond niches were cleared of plaque. None of the patients in this group had trismus of the masticatory muscles or tenderness of the submandibular lymph nodes. In the control group, after tonsillectomy, pain when swallowing persisted until the 5th–7th day; the tonsil niches were cleared of plaque by the 7th–9th day. In 4 out of 10 patients, trismus of the masticatory muscles and the phenomenon of submandibular lymphadenitis of varying severity were noted.

Analysis of the microbial flora after treatment revealed the antibacterial effect of stopangin: in 70% of patients after a course of treatment with the drug, normal flora was noted in throat smears, while in the group receiving traditional therapy, pathogenic bacteria were not detected in 55% of patients.

No side effects were identified in the stopangin treatment group. Most children noted the pleasant taste of the drug.

The results of the study indicate the beneficial complex effect of the drug stopangin on children with chronic tonsillitis and after tonsillectomy.

• The use of the drug stopangin in children with chronic tonsillitis leads to a reduction in treatment time compared to traditional therapy due to the antiseptic and anti-inflammatory properties of the drug.
• The antimicrobial and antimycotic properties of the drug lead to faster disappearance of plaque and more effective sanitation of the oropharyngeal mucosa compared to traditional therapy.
• The use of stopangin can reduce the severity of pain in patients with chronic tonsillitis and children after tonsillectomy.

Literature

1. Garashchenko T. I., Bogomilsky M. R., Shishmareva E. V. New approaches to the treatment of exacerbations of chronic tonsillitis in children // Children's infections. 2004. No. 1.
2. Ponomarev L. E. et al. The influence of chronic tonsillitis on the formation of a group of frequently ill children from preschool institutions // News of otorhinolaryngology and logopathology. 1995. No. 3 (4).
3. Palchun V. T., Kryukov A. I. Otorhinolaryngology. M.: Litera, 1997.
4. Polyakova T. S., Polyakova E. P. Chronic tonsillitis: diagnosis, treatment, prevention // Breast cancer. 2004. T. 12. No. 2.
5. Lopatin A.S. //RMJ. 2000. T. 2. No. 2.

N. V. Ziborova , Candidate of Medical Sciences S. A. Loseva Research Institute of Pediatric and Agricultural Chemistry, Moscow

Release form

Solution for topical use, 0.1%. 100 ml in a dark glass bottle with a screw-on propylene cap with tamper evident and a measuring cap. 1 fl. in a cardboard pack.

Spray for topical use, 0.2%. 30 ml in a bottle made of PE or polyethylene terephthalate, equipped with a mechanical sprayer and a cap to protect the sprayer. 1 fl. complete with an applicator or an applicator with a rotary lever in a cardboard box. The applicator or applicator with a rotating arm can be either in a PE bag or without it.

Nosological classification (ICD-10)

• A69.1 Other Vincent infections
• B37.0 Candidal stomatitis
• C06 Malignant neoplasm of other and unspecified parts of the mouth
• J02 Acute pharyngitis
• J03 Acute tonsillitis [tonsillitis]
• J31.2 Chronic pharyngitis
• K05 Gingivitis and periodontal diseases
• K05.3 Chronic periodontitis
• K12 Stomatitis and related lesions
• K12.0 Recurrent oral aphthae
• K13.7 Other and unspecified lesions of the oral mucosa
• K14.0 Glossitis
• R19.6 Bad breath [bad breath]
• S01.5 Open wound of lip and oral cavity
• S10.1 Other and unspecified superficial injuries of the throat
• Z100* CLASS XXII Surgical practice
• Z54.0 Convalescent period after surgery